Prognostic Importance of Plasma NT-pro BNP in Chronic Heart Failure in Patients Treated with a Beta-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) Trial

Overview

Journal Eur J Heart Fail

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2007 Aug 19

PMID 17693380

Citations 19

Authors

Lars G Olsson

Karl Swedberg

John G F Cleland

Phillip A Spark

Michel Komajda

Marco Metra

Christian Torp-Pedersen

Willem J Remme

Armin Scherhag

Philip Poole-Wilson

Affiliations

Soon will be listed here.

Abstract

Background: Plasma levels of N-terminal pro-brain natriuretic peptide (NT-pro BNP) are increased in patients with chronic heart failure (CHF). Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis.

Objectives: To assess the prognostic importance of NT-pro BNP at baseline and during follow-up, in patients in whom beta-blocker therapy is initiated.

Methods: In COMET, 3029 patients with CHF in NYHA class II-IV and EF<35% were randomised to carvedilol or metoprolol tartrate and were followed for an average of 58 months. Blood samples were collected for the measurement of NT-pro BNP at baseline (n=1559) and during follow-up (n=309).

Results: Baseline plasma concentrations of NT-pro BNP above the median (1242 pg/ml) were associated with higher all-cause mortality (RR 2.77; 95% CI 2.33-3.3, p<0.001). Patients who achieved NT-pro BNP levels<400 pg/ml during follow-up had a lower subsequent mortality (RR 0.32; 95% CI 0.15-0.69, p=0.004).

Conclusions: The plasma concentration of NT-pro BNP is a powerful predictor of mortality in patients with CHF. Patients who achieve an NT-pro BNP of <400 pg/ml subsequent to treatment with a beta-blocker have a favourable prognosis.

Citing Articles

Plasma renin activity variation following admission predicts patient outcome in acute decompensated heart failure with reduced and mildly reduced ejection fraction.

Azuma K, Nishimura K, Min K, Takahashi K, Matsumoto Y, Eguchi A Heliyon. 2023; 9(2):e13181.

PMID: 36747544 PMC: 9898650. DOI: 10.1016/j.heliyon.2023.e13181.

Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study.

Park C, Park J, Lee H, Kang S, Yoo B, Jeon E Cardiovasc Drugs Ther. 2022; 37(3):529-537.

PMID: 35066737 DOI: 10.1007/s10557-021-07238-3.

N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID-19 in a Nationwide Hospitalized Cohort.

ODonnell C, Ashland M, Vasti E, Lu Y, Chang A, Wang P J Am Heart Assoc. 2021; 10(24):e022913.

PMID: 34889112 PMC: 9075235. DOI: 10.1161/JAHA.121.022913.

Sex Differences in Time-Dependent Changes in B-Type Natriuretic Peptide in Hypertrophic Cardiomyopathy.

Enzan N, Matsushima S, Ide T, Kaku H, Tohyama T, Funakoshi K Circ Rep. 2021; 3(10):594-603.

PMID: 34703937 PMC: 8492405. DOI: 10.1253/circrep.CR-21-0110.

NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.

Schmitt W, Ruhs H, Burghaus R, Diedrich C, Duwal S, Eissing T Clin Pharmacol Ther. 2021; 110(2):498-507.

PMID: 33630302 PMC: 8360001. DOI: 10.1002/cpt.2222.